Navigation Links
DxTech and Nicholas Piramal in POC Diagnostics Alliance
Date:4/30/2008

DxTech Enters Into Long-Term Strategic Alliance With Nicholas Piramal for

Point-of-Care Diagnostic Testing System

MERRIMACK, New Hampshire, April 30 /PRNewswire/ -- DxTech LLC ("DxTech"), an innovation company focused on putting high-quality diagnostic information in the hands of physicians in real time, has entered into a long-term strategic alliance with Nicholas Piramal India Limited ("NPIL"), one of the largest pharmaceutical and healthcare companies in India. The alliance includes a License and Development Agreement relating to DxTech's proprietary technology, a Distribution Agreement and an agreement to establish a joint venture between the companies for the marketing and sales of the commercial product.

DxTech is developing the fully-integrated, Vantix(TM) point-of-care ("POC") diagnostics platform based on proprietary, electrochemical sensor technology that has unparalleled sensitivity and dynamic range. This combination will allow DxTech to bring two points of differentiation to the POC market that cannot be realized by any other POC technology currently available: the capability to conduct simultaneous diagnostic immunoassays and general chemistries on a single cartridge delivering a uniquely broad range of tests.

In addition to its core focus on the US$48 billion routine diagnostic market in the US, DxTech's Vantix(TM) platform also has the added potential to transform diagnostic testing in a range of other emerging markets, including Asia, parts of Europe, and Central and Latin America. In these markets, the Vantix(TM) platform could reduce or eliminate the need for expensive, centralised laboratory infrastructures and replace them with equally accurate testing that has a more favourable cost profile, distributed across each POC.

The Vantix(TM) platform is designed to meet or exceed the performance levels established by US reference laboratories, to provide a complete solution from sample collection thr
'/>"/>

SOURCE DxTech and Nicholas Piramal
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
2. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
3. Strategic Diagnostics Updates Roth Conference Presentation Time
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
8. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
9. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
10. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
11. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , COLUMBUS, Ohio, Nov. 30 /PRNewswire/ -...ort for one of the nation,s first minority busines...eld in Cleveland December 3, is called "Transformi...y Business Early-Stage Capital Summit." It will fe...al minority business leaders and local minority en...
(Date:11/30/2009)..., , ROCKVILLE, Md., Nov. 30 /PRNewswire-Fi...cal-stage vaccine company, announced today that th...alth Care Conference 2009 on December 2, 2009 at 1...k. Novavax will provide an overview of the compan...ogress and upcoming milestones. A link to the liv...
(Date:11/30/2009)..., , ROCKVILLE, Md., Nov. 30 /PRNewswire-Fi...ed today it has completed enrollment in the Phase ...nza (2008/2009 recommended strains) VLP vaccine ca... (older adults). This randomized, double-blind, a...lerability and immunogenicity of two different dos...
(Date:11/30/2009)..., , SHANGHAI, Nov. 30 /PRNewswire-...pharmaceutical, biotechnology, and medical-device ...operations in China and the United States,announc...ology Fast 50 China,2009 list for the fifth consec...wing companies in China,s technology, media, and t...
Breaking Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2
... Just as silicon is the wonder material for the co...he materials responsible for the next evolutionary...inary properties have identified them as having th... In particular, it is widely believed that carbon ... level. Many people expect the hugely popular LCD ...
...here is nothing new about combining two materials ...roperties than the originals. Fibreglass has been ...the construction industry is built on reinforced c... on the act with nanotechnologists working out how...n ideal manner. , Researchers from Trinity Colleg...
...S, Nov. 21 HealthpointCapital Partners II, L.P., ...ic medical devices,announced today that, through i...has acquired Paris-based Ideal Medical Products, S...older and will remain principal,shareholder of lea...n McCormick, a Managing Director of HealthpointCap...
Other Biology Technology:FED-TVs with carbon nanotube technology could supersede plasma and LCD flat screens 2HealthpointCapital to Acquire Ideal Medical Products 2
(Date:11/30/2009)..., , VILNIUS, Lithuania, Nov. 30 /PRNe...ology.com ), a provider of high-precision biometri...w upgrades in the company,s core product line: Ve...ial recognition and MegaMatcher 3.1 SDK for larg...identification systems (AFIS). Expanded capabiliti...
(Date:11/26/2009)...Ecologists have at last worked out a way of using ...ize of bird populations. This is the first time so...ranslated into accurate estimates of bird species,...in the British Ecological Society,s Journal of Ap... could lead to a major advance in our ability to m...
(Date:11/26/2009)...MRSA (methicillin-resistant Staphylococcus Aureus...nihilation as low-temperature plasma prototype dev...y and unfailing bactericidal cocktails. , Two pr...ient disinfection of healthy skin (e.g. hands and ...a can pose a lethal threat; and another to shoot b...
Breaking Biology News(10 mins):New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Ecologists sound out new solution for monitoring cryptic species 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 1COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 2Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 1Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 1Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 4
... way that had never been observed in any animal be... Biology, a Cell Press publication. The discoveryw...s that the ability to perceive circular polarized ...unication. , Mantis shrimp ventured into a new di...versity of Queensland in Australia. Also known as ...
...se is a rare, devastating illness in which nerve c... deteriorate. One form of it, Lou Gehrigs disease ...r to the public in the lives of scientist Stephen ...ms Tuesdays with Morrie was written. , For most ...hy these people develop the disease, which causes ...
... the evening of April 17th, in Philadelphia, follo...cience and the spirit of discovery, nine individua...nd two will be presented with prestigious Bower Aw...ursor to the Nobel Prize, are awarded for outstand... impacted and enhanced the quality of human life a...
Other Biology News:Mantis shrimp vision reveals new way that animals can see 2Mantis shrimp vision reveals new way that animals can see 3Motor neuron disease and toxic substances: Possible link? 2Motor neuron disease and toxic substances: Possible link? 3Science and technology take center stage this election year 2Science and technology take center stage this election year 3Science and technology take center stage this election year 4Science and technology take center stage this election year 5Science and technology take center stage this election year 6
Sheep Anti-Human CATHEPSIN G Polyclonal Antibody, Unconjugated from AbD Serotec
DMRIE-C Reagent from Invitrogen
Rabbit Anti-TRANSFERRIN RECEPTOR Polyclonal Antibody, Unconjugated from AbD Serotec
Magnetic Separator (Re-usable) from BioVision
Biology Products: